Skip to main
MIST
MIST logo

MIST Stock Forecast & Price Target

MIST Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 50%
Hold 17%
Sell 0%
Strong Sell 0%

Bulls say

Milestone Pharmaceuticals Inc. is well-positioned for positive growth, having demonstrated statistically significant improvements in patient-reported outcomes related to etripamil, which suggests strong customer satisfaction and treatment efficacy. The company has increased its estimated market share in PSVT to 35% and achieved a 100% probability of success for its upcoming CARDAMYST program, highlighting confidence in both product performance and market capture. Additionally, successful navigation of regulatory pathways, including FDA agreement for a streamlined Phase 3 program for AFib-RVR, reinforces the potential for robust value creation for shareholders in the near term.

Bears say

Milestone Pharmaceuticals faces a challenging outlook due to the significant competition posed by existing oral rate control therapies, which provide delayed relief compared to etripamil’s rapid-onset action, resulting in uncertainty regarding adoption among patients. Despite the projected peak revenue potential of CARDAMYST being estimated at over $1 billion if approved for PSVT and AFib-RVR, market investors may not fully recognize or appreciate this potential, leading to underpricing of the company's shares. Additionally, the ongoing Phase 2 clinical trial introduces inherent risks that could impact the company's future revenue trajectory and overall market confidence in its product pipeline.

MIST has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 50% recommend Buy, 17% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Milestone Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Milestone Pharmaceuticals Inc (MIST) Forecast

Analysts have given MIST a Buy based on their latest research and market trends.

According to 6 analysts, MIST has a Buy consensus rating as of Jul 1, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $7.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $7.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Milestone Pharmaceuticals Inc (MIST)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.